Cargando…
Recent Advances in Combined Modality Therapy
Combined modality therapy emerged from preclinical data showing that carefully chosen drugs could enhance the sensitivity of tumor cells to radiation while having nonoverlapping toxicities. Recent advances in molecular biology involving the identification of cellular receptors, enzymes, and pathways...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227964/ https://www.ncbi.nlm.nih.gov/pubmed/20413642 http://dx.doi.org/10.1634/theoncologist.2009-S105 |
_version_ | 1782217795778379776 |
---|---|
author | Mierzwa, Michelle L. Nyati, Mukesh K. Morgan, Meredith A. Lawrence, Theodore S. |
author_facet | Mierzwa, Michelle L. Nyati, Mukesh K. Morgan, Meredith A. Lawrence, Theodore S. |
author_sort | Mierzwa, Michelle L. |
collection | PubMed |
description | Combined modality therapy emerged from preclinical data showing that carefully chosen drugs could enhance the sensitivity of tumor cells to radiation while having nonoverlapping toxicities. Recent advances in molecular biology involving the identification of cellular receptors, enzymes, and pathways involved in tumor growth and immortality have resulted in the development of biologically targeted drugs. This review highlights the recent clinical data in support of newer generation cytotoxic chemotherapies and systemic targeted agents in combination with radiation therapy. |
format | Online Article Text |
id | pubmed-3227964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | AlphaMed Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-32279642012-04-25 Recent Advances in Combined Modality Therapy Mierzwa, Michelle L. Nyati, Mukesh K. Morgan, Meredith A. Lawrence, Theodore S. Oncologist New Translational Research in Radiation Oncology: A Tribute to Eli Glatstein Combined modality therapy emerged from preclinical data showing that carefully chosen drugs could enhance the sensitivity of tumor cells to radiation while having nonoverlapping toxicities. Recent advances in molecular biology involving the identification of cellular receptors, enzymes, and pathways involved in tumor growth and immortality have resulted in the development of biologically targeted drugs. This review highlights the recent clinical data in support of newer generation cytotoxic chemotherapies and systemic targeted agents in combination with radiation therapy. AlphaMed Press 2010-04 /pmc/articles/PMC3227964/ /pubmed/20413642 http://dx.doi.org/10.1634/theoncologist.2009-S105 Text en ©AlphaMed Press available online without subscription through the open access option. |
spellingShingle | New Translational Research in Radiation Oncology: A Tribute to Eli Glatstein Mierzwa, Michelle L. Nyati, Mukesh K. Morgan, Meredith A. Lawrence, Theodore S. Recent Advances in Combined Modality Therapy |
title | Recent Advances in Combined Modality Therapy |
title_full | Recent Advances in Combined Modality Therapy |
title_fullStr | Recent Advances in Combined Modality Therapy |
title_full_unstemmed | Recent Advances in Combined Modality Therapy |
title_short | Recent Advances in Combined Modality Therapy |
title_sort | recent advances in combined modality therapy |
topic | New Translational Research in Radiation Oncology: A Tribute to Eli Glatstein |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227964/ https://www.ncbi.nlm.nih.gov/pubmed/20413642 http://dx.doi.org/10.1634/theoncologist.2009-S105 |
work_keys_str_mv | AT mierzwamichellel recentadvancesincombinedmodalitytherapy AT nyatimukeshk recentadvancesincombinedmodalitytherapy AT morganmereditha recentadvancesincombinedmodalitytherapy AT lawrencetheodores recentadvancesincombinedmodalitytherapy |